Nonmyeloablative stem cell transplantation as immunotherapy for kidney cancer and other metastatic solid tumors.
Cytotechnology
; 41(2-3): 197-206, 2003 Mar.
Article
in En
| MEDLINE
| ID: mdl-19002956
ABSTRACT
Over the past few decades, great strides have been made to advance the field of allogeneic hematopoietic stem cell transplantation. The donor immune mediated graft-vs-tumor effect that follows the procedure is now widely accepted as the most effective form cancer immunotherapy available for patients with a variety of advanced hematological malignancies. Recognition that a transplanted immune system could cure patients with treatment refractory leukemia led to the development of ;low-intensity' conditioning regimens, which have improved the safety of the procedure and broadened the application of allogeneic immunotherapy to a growing list of neoplastic diseases. Here we discuss the investigational use of allogeneic transplantation as immunotherapy for patients with metastatic, treatment-refractory solid tumors.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Cytotechnology
Journal subject:
BIOTECNOLOGIA
/
GENETICA
Year:
2003
Document type:
Article
Affiliation country:
United States